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Abstract 
Background: Treatment of metastatic NSCLC patients with immune-checkpoint medicine is intriguing for the 
potential efficacy; however it may be difficult to evaluate the clinical response due to the lack of reliable immune-
monitoring markers up to now and the possibility of radiological pseudo-progression.
Case presentation: Herein we report the case of a patient ex-smoker with adenocarcinoma of the lung, stage IV for 
liver metastases, in progression after cisplatin-based chemotherapy and treated with antiPD-L1 (MPDL3802-Roche 
Genentech) e.v. every 3 weeks in a clinical trial. Treatment with antiPD-L1 was well tolerated and CT scan after 6 weeks 
of treatment showed stabilization of mediastinal lymph nodes, while progression of liver metastases; liver progression 
only was confirmed by further CT-scans. Patient was asymptomatic and it was unclear if we faced a pseudo-progres-
sion in the liver or a real progression. Data about his PDL1 expression were not available because the patient was in 
a clinical trial. Eventually a biopsy of the liver metastasis confirmed that there was a massive neoplastic invasion with 
tumor infiltrating lymphocytes <5 %. We stopped anti-PD-L1 therapy due to progression.
Conclusion: Evaluation of response may be difficult with immune checkpoint inhibitors, in particular radiologic 
images may be a matter of debate; eventually we performed a biopsy to study tumor infiltrating lymphocytes to 
decide whether it was pseudo-progression or real progression.
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Background
Response assessment during anticancer treatment is a 
strategic checkpoint to decide whether keep the patient 
on treatment or stop it and eventually change it. Accord-
ing to the RECIST system, dimensional criteria have 
driven such decision up to now; however, immune-
checkpoint inhibitors have started a paradigm shift. 
There may be a dimensional increase of the tumor, with-
out clinical deterioration and we do not know if refer 
it as pseudo-progression or real progression [1]. Hodi 
et  al. described two types of pseudo-tumor progression 
in melanoma, early and delayed, according to the timing 
of presentation [2], meaning an initial progression fol-
lowed by a further shrinkage of the neoplastic disease, 
without changing of treatment. Although it is not a fre-
quent phenomenon (the incidence of response with dis-
tinct immune-related patterns of response across several 
solid tumors is roughly 4 %), it is extremely important to 
recognize it avoiding inappropriate discontinuation of 
therapy [3, 4].
Response evaluation on immune-checkpoint inhibitors 
is a new and challenging issue for oncologists; although 
response rate is not the ultimate goal, it is a key tool to 
decide whether to keep the patient on treatment. There-
fore we present our case, where the progression of dis-
ease was unclear at the beginning and a histological 
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Case presentation
A 61  year-old, male patient arrived at our Institute in 
September 2014, with an adenocarcinoma of the lung, 
EGFR wild-type and ALK not-translocated, involving the 
mediastinum and the liver where there were three lit-
tle metastatic localizations. His performance status (PS) 
score was 0, he was asymptomatic and his hepatic and 
renal functions were normal. He had already received 4 
cycles of cisplatin combined with pemetrexed, obtaining 
stable disease; he was then put on maintenance treat-
ment with pemetrexed and eventually after 5 cycles he 
developed progression at the liver. The patient had been 
referred to us for entering a clinical trial. We enrolled 
him into a protocol with anti PD-L1 (MPDL3802-Roche 
Genentech), 10  mg/kg i.v. every 3  weeks. His PD-L1 
status was not disclosed, being in a clinical trial. After 
6  weeks the computed tomography (CT)-scan dem-
onstrated progression of all the hepatic lesions (Fig.  1), 
while the mediastinum remained stable; after 12  weeks 
CT-scan again showed progression at the liver, 18 weeks 
later radiologic evaluation demonstrated once more 
progression of the three liver nodules and progression 
of the mediastinal lymph nodes. No new lesions were 
observed. Liver function remained normal and his PS 
was 0.
To understand the underlying process, whether it was 
pseudo-progression or real progression, after 12 weeks of 
treatment with anti-PD-L1 we performed two biopsies of 
one liver metastasis; we chose to biopsy the liver locali-
zation, because it was easy to reach and in progression 
from the very beginning of treatment.
Methods
Surgical specimens were sampled according to cur-
rent protocols. Formalin-fixed, paraffin-embedded tis-
sue samples were obtained, 4-μm sections were stained 
with hematoxylin and eosin 2.5-μm sections were cut 
and immunohistochemical analysis was performed in 
an automated system (Benchmark-XT, Ventana, Tucson, 
AZ, US). The following primary antibodies were used: 
TTF-1 (monoclonal antibody, clone SP141, pre-diluted; 
Ventana, Tucson, AZ, US), CD45 (monoclonal anti-
body, clone 2B11&PD7/26; prediluted; Ventana, Tucson, 
AZ, US) and CD3 (monoclonal antibody, clone 2GV6; 
Ventana, Tucson, AZ, US). Color was developed with 
3.3′-diaminobenzidine (DAB) and slides were counter-
stained with Meyer’s hematoxylin. Appropriate positive 
and negative controls were concurrently done.
Conclusions
We analyzed the percentage of lymphocyte infiltration 
versus the cancer burden, overall we found less than 5 % 
of lymphocytes (Fig. 2). There is no robust existing litera-
ture about the typical percentage of lymphocytes infil-
trating a tumor as a sign of immune- response against 
the tumor; there is one report about a case of melanoma, 
where a cutaneous leg lesion obtained enlargement dur-
ing the early phases of treatment with ipilimumab and 
was excised because of bleeding; histopathology of the 
lesion showed a high proportion of infiltrating T lympho-
cytes, roughly more than 30 %, while the outcome of the 
patient turned out to be positive, with a long-lasting sta-
bility for more than 20 months [5].
Fig. 1 Metastatic localizations in the liver (VII and VIII segment) in the CT-scan of September 2014 (on the left), before treatment with antiPD-L1, 
and November 2014, after 6 weeks of treatment with antiPD-L1 (on the right) (H&E, ×20). The arrow shows the metastatic localization where the 
biopsy was performed
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Since we did not find any dense infiltrate of lymphocytes 
in the liver biopsies, we concluded that our patient had a 
real progression and stopped the treatment with anti PD-L1.
Up to now there are no available and reliable predic-
tive factors for immune-checkpoint inhibitors neither 
dynamic predictive markers of efficacy; the tumoral 
response may be difficult to assess for the pseudo-pro-
gression phenomena [3].
Until a reliable clinical or biological predictor marker of 
activity for this new class of anticancer drugs is available and 
until radiological evaluation of response is based on dimen-
sion of cancer nodules, the analysis of response could be a 
real challenge in patients on treatment with immune-check-
point inhibitors. In our case, the presence of an easily percu-
taneously accessible metastasis allowed a bioptic assessment 
to understand the real efficacy of the ongoing treatment.
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Fig. 2 Histologic features of the metastatic infiltrate in the liver (a), and immunohistochemistry for TTF-1 (b), CD45 (c) and CD3 (d) (H&E, ×20)
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